JP2013509432A - ヘルペスウイルス感染を阻害するペプチド組成物および方法 - Google Patents

ヘルペスウイルス感染を阻害するペプチド組成物および方法 Download PDF

Info

Publication number
JP2013509432A
JP2013509432A JP2012537122A JP2012537122A JP2013509432A JP 2013509432 A JP2013509432 A JP 2013509432A JP 2012537122 A JP2012537122 A JP 2012537122A JP 2012537122 A JP2012537122 A JP 2012537122A JP 2013509432 A JP2013509432 A JP 2013509432A
Authority
JP
Japan
Prior art keywords
seq
residues
peptide
sequence
hcmv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012537122A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013509432A5 (https=
Inventor
リリア アイ メルニク
ロバート エフ ギャリー
シンディ エイ モリス
Original Assignee
ザ アドミニストレイターズ オブ ザ テューレイン エデュケイショナル ファンド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ アドミニストレイターズ オブ ザ テューレイン エデュケイショナル ファンド filed Critical ザ アドミニストレイターズ オブ ザ テューレイン エデュケイショナル ファンド
Publication of JP2013509432A publication Critical patent/JP2013509432A/ja
Publication of JP2013509432A5 publication Critical patent/JP2013509432A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/045—Cytomegalovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2012537122A 2009-10-30 2010-10-29 ヘルペスウイルス感染を阻害するペプチド組成物および方法 Pending JP2013509432A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28011209P 2009-10-30 2009-10-30
US61/280,112 2009-10-30
PCT/US2010/054743 WO2011053798A2 (en) 2009-10-30 2010-10-29 Peptide compositions and methods for inhibiting herpesvirus infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016014209A Division JP6209228B2 (ja) 2009-10-30 2016-01-28 ヘルペスウイルス感染を阻害するペプチド組成物および方法

Publications (2)

Publication Number Publication Date
JP2013509432A true JP2013509432A (ja) 2013-03-14
JP2013509432A5 JP2013509432A5 (https=) 2013-12-19

Family

ID=43923008

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012537122A Pending JP2013509432A (ja) 2009-10-30 2010-10-29 ヘルペスウイルス感染を阻害するペプチド組成物および方法
JP2016014209A Expired - Fee Related JP6209228B2 (ja) 2009-10-30 2016-01-28 ヘルペスウイルス感染を阻害するペプチド組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016014209A Expired - Fee Related JP6209228B2 (ja) 2009-10-30 2016-01-28 ヘルペスウイルス感染を阻害するペプチド組成物および方法

Country Status (6)

Country Link
US (2) US8802106B2 (https=)
EP (1) EP2493911B1 (https=)
JP (2) JP2013509432A (https=)
AU (1) AU2010313339B2 (https=)
CA (1) CA2779459A1 (https=)
WO (1) WO2011053798A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024508799A (ja) * 2021-02-24 2024-02-28 ファイザー・インク ヒトサイトメガロウイルス糖タンパク質ｂポリペプチドにおける新規創薬可能領域およびその使用方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2627352B1 (en) * 2010-10-15 2017-05-10 GlaxoSmithKline Biologicals S.A. Cytomegalovirus gb antigen
GB201312133D0 (en) * 2013-07-05 2013-08-21 Univ Birmingham Immunotherapy
JP6679484B2 (ja) * 2013-12-11 2020-04-15 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド ヒトヘルペスウイルス三量体糖タンパク質Ｂ、三量体ｇＢを含むタンパク質複合体、及びワクチンとしてのそれらの使用
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3474887A1 (en) * 2016-06-27 2019-05-01 AiCuris Anti-infective Cures GmbH Hcmv entry inhibitors
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN111675752B (zh) * 2020-03-16 2023-07-07 成都奥达生物科技有限公司 一种冠状病毒膜融合抑制剂及其药物用途
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
CN115894708B (zh) * 2022-08-16 2023-10-10 青岛大学 一种人巨细胞病毒抗原表位嵌合肽及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0994095A (ja) * 1986-03-07 1997-04-08 Cogent Ltd Ｈｃｍｖの糖タンパク質に対する抗体の産生法
JP2005504733A (ja) * 2001-06-26 2005-02-17 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ 新規なヒトサイトメガロウイルス（ｈｃｍｖ）細胞傷害性ｔ細胞エピトープ、ポリエピトープ、それを含む組成物、ならびにその診断、予防および治療上の使用
US20050260199A1 (en) * 2004-05-12 2005-11-24 Teresa Compton Cytomegalovirus disintegrin-like peptides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68929478T2 (de) * 1988-01-29 2004-04-29 Aventis Pasteur Rekombinante CMV-Neutralisierungsproteine
US5514577A (en) 1990-02-26 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide therapies for modulating the effects of herpes viruses
US5633230A (en) * 1990-10-24 1997-05-27 Allelix Biopharmaceuticals, Inc. Treatment of cytomegalovirus infection
US5831001A (en) * 1990-10-24 1998-11-03 Allelix Biopharmaceuticals Inc. Treatment of herpesvirus infection
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
GB9409962D0 (en) * 1994-05-18 1994-07-06 Smithkline Beecham Biolog Novel compounds
CA2295933A1 (en) * 1997-07-03 1999-01-14 Smithkline Beecham Corporation Compounds and methods for treating and screening viral reactivation
US20030036181A1 (en) * 2000-06-30 2003-02-20 Okkels Jens Sigurd Peptide extended glycosylated polypeptides
FR2818279B1 (fr) * 2000-12-15 2005-02-25 Univ Paris Curie Peptide de la glycoproteine b de l'herpesvirus humain 7 utilisable notamment dans un test serologique elisa
DK2311848T3 (da) * 2002-12-23 2013-10-14 Vical Inc Kodon-optimerede polynukleotidbaserede vacciner mod human cytomegalovirus-infektion
US20090181889A1 (en) * 2006-03-08 2009-07-16 University Of Rochester Compositions and methods for detection and treatment of human herpesvirus (hhv)-6
CN101780277A (zh) * 2009-01-15 2010-07-21 鑫品生医科技股份有限公司 含衍生自细胞巨大病毒的免疫原组成物及其使用方法
EP2627352B1 (en) * 2010-10-15 2017-05-10 GlaxoSmithKline Biologicals S.A. Cytomegalovirus gb antigen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0994095A (ja) * 1986-03-07 1997-04-08 Cogent Ltd Ｈｃｍｖの糖タンパク質に対する抗体の産生法
JP2005504733A (ja) * 2001-06-26 2005-02-17 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ 新規なヒトサイトメガロウイルス（ｈｃｍｖ）細胞傷害性ｔ細胞エピトープ、ポリエピトープ、それを含む組成物、ならびにその診断、予防および治療上の使用
US20050260199A1 (en) * 2004-05-12 2005-11-24 Teresa Compton Cytomegalovirus disintegrin-like peptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF VIROLOGY, vol. 76, no. 12, JPN6015001113, 2002, pages 6073 - 6082, ISSN: 0002983382 *
VIROLOGY JOURNAL, vol. 2:49, JPN6015001114, 2005, ISSN: 0002983383 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024508799A (ja) * 2021-02-24 2024-02-28 ファイザー・インク ヒトサイトメガロウイルス糖タンパク質ｂポリペプチドにおける新規創薬可能領域およびその使用方法

Also Published As

Publication number Publication date
US8802106B2 (en) 2014-08-12
CA2779459A1 (en) 2011-05-05
EP2493911A4 (en) 2014-01-01
AU2010313339A1 (en) 2012-06-07
WO2011053798A2 (en) 2011-05-05
EP2493911A2 (en) 2012-09-05
WO2011053798A3 (en) 2011-09-22
US9434769B2 (en) 2016-09-06
EP2493911B1 (en) 2017-10-18
JP2016128477A (ja) 2016-07-14
JP6209228B2 (ja) 2017-10-04
AU2010313339B2 (en) 2016-05-26
US20150119318A1 (en) 2015-04-30
US20130005648A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
JP6209228B2 (ja) ヘルペスウイルス感染を阻害するペプチド組成物および方法
CN111560076B (zh) 一种嵌合抗原受体免疫细胞及其制备方法和应用
US20090170764A1 (en) Compositions containing anti-hiv peptides and methods for use
Chaubey et al. A PNA-transportan conjugate targeted to the TAR region of the HIV-1 genome exhibits both antiviral and virucidal properties
CN109535232B (zh) 多肽、其制备方法及抑制艾滋病病毒的用途
AU2009281992A1 (en) Combination therapy of HIV fusion/entry inhibitors targeting gp41
US9221874B2 (en) Antiviral peptides against influenza virus
WO2026021236A1 (zh) 可抑制类mers冠状病毒感染的多肽及其应用
JP2007536910A (ja) ウイルス感染の治療
US10745448B2 (en) Antiviral peptide and use therefor
CN110869040A (zh) 肽及其用作抗病毒剂的用途
Pan et al. A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stability
AU2022237899A1 (en) Compounds for use in the treatment of an enveloped virus infection
US11155582B2 (en) Antiviral peptide and use thereof
WO2005060541A2 (en) Peptides and methods for inducing cellular resistance to infection
US20230235301A1 (en) Compounds and Methods for Treating, Ameliorating, or Preventing Herpes Ocular Keratitis
Annett et al. A modified cyclosporine enhances lentivector transduction ex vivo and in vivo by degrading IFITM3
WO2021258218A1 (en) Use of soluble nrp1 polypeptides for the treatment of coronavirus infections

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150408

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150928